Moderna’s focus on COVID vaccines has hurt its business as demand decreases. It’s working on a personalized cancer vaccine with Merck, showing progress. Pfizer diversified post-pandemic, while Moderna’s revenue fell from $18.9B in 2022 to $3.1B. The market cap remains high at $10.4B, uncertain about future growth.

The personalized cancer vaccine, mRNA-4157, could be a game-changer for Moderna, reducing the risk of recurrence or death by 49% in high-risk patients. Despite its past valuation, the company faces uncertainties in future growth, making it a potential one-hit wonder.

Consideration before investing in Moderna: The Motley Fool Stock Advisor team didn’t include it in their top 10 stock picks. Instead, they identified other stocks with the potential for significant returns. Don’t miss out on potentially lucrative investment opportunities with their recommendations.

Read more at Yahoo Finance: Why Moderna Might Be a One-Hit Wonder